A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer

Annals of Oncology

Volumn 27, Issue 9, 2016, Pages 1712-1718

  Lacouture, Mario E ^a   Keefe, D M ^b   Sonis, S ^c   Jatoi, A ^d   Gernhardt, D ^e   Wang, T ^e   Doherty, J P ^f   Giri, N ^g   Nadanaciva, S ^e   O'Connell, J ^f   Sbar, E ^h   Piperdi, B ⁱ   Garon, E B ^j  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MAYO CLINIC   (United States)

^e Pfizer Oncology   (United States)

^f Pfizer Ltd   (United States)

^g Pf Izer Oncology Inc   (United States)

^h Pfizer Oncology   (United States)

ⁱ ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Dacomitinib; Dermatologic adverse events; Epidermal growth factor receptor; Gastrointestinal adverse events; Non small cell lung cancer

Indexed keywords

ALCLOMETASONE; ANTIBIOTIC AGENT; DACOMITINIB; DERMATOLOGICAL AGENT; DOXYCYCLINE; DRUG METABOLITE; LOPERAMIDE; PF 05199265; PLACEBO; PROBIOTIC AGENT; STEROID; UNCLASSIFIED DRUG; QUINAZOLINONE DERIVATIVE;

ACNE; ADVANCED CANCER; ADVERSE DRUG REACTION; ARTICLE; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; ERYTHRODERMA; HUMAN; LACERATION; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAIL DISCOLORATION; NAIL DISEASE; NON SMALL CELL LUNG CANCER; PARONYCHIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN EXFOLIATION; SKIN FISSURE; SKIN INFECTION; SKIN ULCER; ADULT; AGED; CHEMICALLY INDUCED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; GASTROINTESTINAL DISEASE; MALE; MIDDLE AGED; MUTATION; PATHOLOGY; QUALITY OF LIFE; SKIN DISEASE; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; MUTATION; QUALITY OF LIFE; QUINAZOLINONES; SKIN DISEASES; TREATMENT OUTCOME;

EID: 84995550752     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw227     Document Type: Article

References (9)

1. Mok T, Lee K, Tang M, Leung L. Dacomitinib for the treatment of advanced or metastatic non-small-cell lung cancer. Future Oncol 2014; 10: 813-822.
2. Melosky B, Leighl NB, Rothenstein J et al. Management of EGFR TKI-induced dermatologic adverse events. Curr Oncol 2015; 22: 123-132.
3. Hirsh V, Blais N, Burkes R et al. Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors. Curr Oncol 2014; 21: 329-336.
4. Chren MM, Lasek RJ, Quinn LM et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol 1996; 107: 707-713.
5. Stiff PJ, Erder H, Bensinger WI et al. Reliability and validity of a patient selfadministered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous hematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant 2006; 37: 393-401.
6. Lacouture ME, Mitchell EP, Piperdi B et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28: 1351-1357.
7. Jatoi A, Rowland K, Sloan JA et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 2008; 113: 847-853.
8. Melosky B, Anderson H, Burkes RL et al. Pan Canadian Rash trial: a randomized phase III trial evaluating the impact of a prophylactic skin treatment regimen on epidermal growth factor receptor-tyrosine kinase inhibitor-induced skin toxicities in patients with metastatic lung cancer. J Clin Oncol 2016; 34: 810-815.
9. Delia P, Sansotta G, Donato V et al. Use of probiotics for prevention of radiationinduced diarrhea. World J Gastroenterol 2007; 13: 912-915.